DocSym
β
Searchsearch
Search
(G04.1) Human t-cell lymphotropic virus associated myelopathy
More details coming soon
408 330 in individuals diagnosis human t-cell lymphotropic virus associated myelopathy confirmed
31 540 deaths with diagnosis human t-cell lymphotropic virus associated myelopathy
8% mortality rate associated with the disease human t-cell lymphotropic virus associated myelopathy
Diagnosis human t-cell lymphotropic virus associated myelopathy is diagnosed Men are 5.56% more likely than Women
215 521
Men receive the diagnosis human t-cell lymphotropic virus associated myelopathy
16 137 (7.5 %)Died from this diagnosis.
100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0
192 809
Women receive the diagnosis human t-cell lymphotropic virus associated myelopathy
15 403 (8.0 %)Died from this diagnosis.
Risk Group for the Disease human t-cell lymphotropic virus associated myelopathy - Men aged 55-59 and Women aged 50-54
In Men diagnosis is most often set at age 0-89
Less common in men the disease occurs at Age 90-95+Less common in women the disease occurs at Age 95+
In Women diagnosis is most often set at age 0-94
Disease Features human t-cell lymphotropic virus associated myelopathy
Absence or low individual and public risk
Human t-cell lymphotropic virus associated myelopathy - what does this mean
Human t-cell lymphotropic virus associated myelopathy is a neurological disorder caused by infection with the human t-cell lymphotropic virus (htlv-1). it affects the spinal cord and is characterized by progressive weakness and stiffness of the lower limbs, leading to difficulty in walking and balance. other symptoms may include pain, numbness, and bladder and bowel dysfunction.
What happens during the disease - human t-cell lymphotropic virus associated myelopathy
Human t-cell lymphotropic virus (htlv-1) associated myelopathy is a neurological disorder caused by the infection of the spinal cord with the htlv-1 virus. the virus is believed to enter the spinal cord through the bloodstream, where it infects and destroys the myelin sheath surrounding the nerve cells, resulting in inflammation and demyelination of the spinal cord. this leads to a range of neurological symptoms such as weakness, numbness, and pain in the lower limbs, spasticity, and bladder and bowel dysfunction.
Clinical Pattern
More details coming soon
How does a doctor diagnose
- Complete physical examination
- Complete neurological examination
- Laboratory tests including complete blood count, chemistry panel, and HIV serology
- Cerebrospinal fluid analysis
- Imaging studies, such as MRI of the spine
- Electrophysiological studies, such as nerve conduction studies and electromyography
- Urine toxicology screen
- Genetic testing
- T-cell receptor gene rearrangement studies
Treatment and Medical Assistance
Main goal of the treatment: To reduce the symptoms of Human T-cell lymphotropic virus associated myelopathy.
- Medication to suppress the virus
- Physical therapy to improve mobility
- Occupational therapy to improve daily living skills
- Speech therapy to improve communication
- Nutritional counseling to improve overall health
- Counseling to help with emotional and social support
30 Days of Hospitalization Required
Average Time for Outpatient Care Not Established
Human t-cell lymphotropic virus associated myelopathy - Prevention
The best way to prevent human t-cell lymphotropic virus associated myelopathy is to practice safe sex, avoid sharing needles, and get tested for hiv regularly. vaccines are also available to help prevent the spread of the virus.